Welcome to our dedicated page for Applied UV news (Ticker: AUVI), a resource for investors and traders seeking the latest updates and insights on Applied UV stock.
Applied UV, Inc. (AUVI) delivers innovative UV-based disinfection systems and custom mirror solutions for healthcare and hospitality sectors. This page provides investors and industry professionals with direct access to official announcements, financial updates, and strategic developments from the company.
Find timely updates on product launches, regulatory milestones, and partnership agreements that shape AUVI’s position in smart building technology and infection control markets. Content includes earnings reports, technology patents, and market expansion initiatives, offering insights into the company’s operational priorities.
Bookmark this page to stay informed about AUVI’s advancements in automated sterilization systems and decorative mirror designs. Regular updates ensure you never miss critical information affecting the company’s performance across global healthcare and hospitality markets.
Applied UV (NASDAQ:AUVI) announced a new purchase order through its subsidiary, SteriLumen, from Insightra Medical for the Airocide™ air purification system at the Dubai Creek Golf & Yacht Club Resort. The second phase includes 54 Airocide™ units for the resort’s Park Hyatt-managed vacation villas. A third phase to install SteriLumen UVC sterilization devices is planned. This initiative aims to validate the effectiveness of the technology and expand its offerings to hotels globally. The FDA has recognized the Airocide™ system for its ability to reduce viral exposure risks.
Applied UV (NASDAQ:AUVI) announced a non-binding letter of intent to acquire key assets from Akida Holdings, including rights to the Airocide™ air purification system, potentially valued at $12 million in stock. This acquisition aims to enhance infection prevention technology in sectors like healthcare and hospitality, leveraging Airocide's proven ability to eliminate airborne pathogens. The deal is contingent on due diligence and board approvals, with no guarantee it will finalize by the March 2021 deadline. Airocide is recognized for its effectiveness against various airborne microorganisms.
Applied UV, Inc. (NASDAQ:AUVI) announced an exclusive licensing and joint development agreement with Axis Lighting, Inc. to create innovative LED-based UV-C technologies targeting pathogen neutralization in hospitals across North America. The partnership aims to enhance healthcare environments by leveraging SteriLumen's patented disinfection technology and Axis Lighting's industry expertise. Royalties will be paid to SteriLumen on sales of developed products, signifying a strategic move to address the growing demand for efficient infection prevention solutions.
Applied UV (NASDAQ: AUVI) announced that its subsidiary, SteriLumen, has filed a patent application for a UV light sanitizing solution retrofittable to ATMs, aimed at disinfecting surfaces like keyboards and touchscreens. This technology addresses pathogen transmission on commonly touched surfaces, notably ATMs, which numbered approximately 470,000 in the U.S. as of 2018. The company emphasizes that SteriLumen's UVC devices effectively neutralize pathogens such as E. coli and coronavirus, enhancing their patent portfolio to address public health concerns.
Applied UV, Inc. (NasdaqCM:AUVI) announced that its subsidiary, SteriLumen, secured a purchase order for its patented Airocide™ Air Quality-Improvement™ System at the Dubai Creek Golf & Yacht Club Resort. This installation will enhance air purification in various public spaces and residential villas, aimed at combating airborne pathogens. The Airocide system, leveraging NASA technology, is FDA classified and clinically proven to effectively eliminate harmful microorganisms. This partnership highlights SteriLumen's role as a key player in the hospitality sector across the U.S. and the Greater Middle East.
Applied UV (NASDAQ:AUVI) announced that its subsidiary, SteriLumen, installed its Disinfecting System in the first of 17 patient bathrooms at Mount Sinai's Morningside Hospital. This installation supports a study to validate the technology's effectiveness against pathogens, including human coronaviruses. Results are expected by Q2 2021, with findings to be published in a peer-reviewed journal. Previous reports indicated that SteriLumen can effectively reduce pathogens by over 99.99%. CEO Q Saeed emphasized the milestone of deploying their technology in a top U.S. medical institution.
Applied UV (NASDAQCM:AUVI) has announced that its subsidiary, SteriLumen, will serve as the exclusive distributor of the Airocide Air Quality-Improvement System in the U.S. and Greater Middle East. The Airocide system, originally developed for NASA, effectively eliminates airborne pathogens and is FDA Class II listed. The partnership aims to enhance indoor air quality in the hospitality sector, vital during the ongoing pandemic. Financial details of the agreement were not disclosed.
Applied UV, Inc. (NasdaqCM:AUVI) successfully closed its initial public offering of 1,000,000 shares at $5.00 each on September 2, 2020, plus an additional 150,000 shares from the underwriter's overallotment. The total gross proceeds amounted to $5.75 million before expenses.
The company's products utilize UVC technology for pathogen destruction and demonstrated effectiveness against the OC43 coronavirus, likely extending to SARS-CoV-2. Applied UV aims to address infection prevention across multiple sectors including healthcare and hospitality.
Applied UV, Inc. (NasdaqCM:AUVI), an infection prevention technology company, announced the exercise of an overallotment option for its IPO, allowing Network 1 Financial Securities to purchase an additional 150,000 shares at $5.00 each. The IPO began trading on August 31, 2020, and is set to close on September 2, 2020. Applied UV’s technology utilizes UVC light to eliminate pathogens, with laboratory tests showing effectiveness against the OC43 human coronavirus, which is similar to SARS-CoV-2. The company operates two subsidiaries focused on healthcare and hospitality sectors.
Applied UV, Inc. (NASDAQ:AUVI) has priced its initial public offering (IPO) at $5.00 per share, offering 1,000,000 shares and aiming for gross proceeds of approximately $5 million. The IPO is set to close on September 2, 2020, pending customary conditions. Network 1 Financial Securities, Inc. leads the underwriting team and has an option for an additional 150,000 shares for over-allotments. The company focuses on infection prevention utilizing UVC technology to combat pathogens, with promising testing results against the coronavirus.
